FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

ashington,	$D \subset$	20540
vasilington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per respons	e: 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Siu Christine</u>				Mo	2. Issuer Name and Ticker or Trading Symbol Monte Rosa Therapeutics, Inc. [GLUE] 3. Date of Earliest Transaction (Month/Day/Year)						(Ch	eck all appli X Directo	cable)	Person(s) to Is 10% Ov Other (s)	vner	
(Last)	(Fi	rst)	(Middle)		06/1	06/14/2023							below)		below)	
MONTE ROSA THERAPEUTICS, INC. 321 HARRISON AVENUE, SUITE 900				4. If /	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street)	N M	A	02118			<u> </u>	I Oh E	1 (a	\ Tuo :: a a a	ation los	dia a ti a sa		Form f Persor		than One Repo	orting
(City)	(Si	tate)	(Zip)		$ _{\square}$	Checl	k this box	to inc) Transad licate that a trade defense condi	nsaction was	made pursua	ant to a con		on or written p	olan that is intend	ed to
		Tab	le I - Nor	n-Deriv	ative	Sec	urities	s Ac	quired, Di	isposed (of, or Be	neficial	ly Owne	i		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)						6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	/ Amoun	t (A) or Price		Transac (Instr. 3	tion(s)		Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year) 3A. Deem Execution if any (Month/Day	Date,	Date, Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$6.59	06/14/2023			A		20,500		(1)	06/13/2033	Common Stock	20,500	\$0.00	20,500	D	

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

Remarks:

/s/ Ajim Tamboli, Attorney-in-Fact
** Signature of Reporting Person

06/15/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.